DS Stage III Plasma Cell Myeloma
13
0
0
9
Key Insights
Highlights
Success Rate
82% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
15.4%
2 terminated out of 13 trials
81.8%
-4.7% vs benchmark
0%
0 trials in Phase 3/4
78%
7 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (13)
S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma
NK Cells in Cord Blood Transplantation
Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma
Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma